ArticleMolecular and clinical oncology2026
A prognostic gene signature derived from aging-related genes predicts survival, immune landscape and therapy response in glioma.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas, the most common primary brain tumors, show diverse prognostic outcomes. Differences in gene expression between low-grade gliomas and glioblastoma and the role of aging-related genes highlight the need for robust prognostic models. The present study identified differentially expressed genes (DEGs) and developed a predictive risk model. Using The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) datasets, 29 overlapping aging-related DEGs were identified (|LogFC|>1, adjusted P<0.05). Cox and LASSO regression analyses selected 8 genes for a risk scoring model, validated across datasets and subgroups. Functional and single-cell analyses explored immune microenvironments and drug sensitivities. Additionally, reverse transcription-quantitative PCR (RT-qPCR) was performed to validate the differential expression of these genes in normal astrocytes (HA) and glioblastoma (GBM) cell lines (U251 and U87). The 8-gene model (Netrin-4, retinol-binding protein 1, Twist Family BHLH Transcription Factor 1, growth arrest and DNA damage inducible gamma (GADD45G), NUAK2, glutamate ionotropic receptor kainate type subunit 2, WEE1 and ribonucleotide reductase regulatory subunit) stratified patients into high- and low-risk groups, with high-risk patients showing significantly poorer survival (TCGA, HR=6.84; CGGA, HR=3.72; P<0.001). High-risk tumors were enriched in cell cycle and senescence pathways and exhibited elevated immune checkpoint expression and reduced chemotherapeutic sensitivity. Single-cell analysis revealed differential GADD45G expression in M1 and M2 macrophages, suggesting a role in immune evasion. RT-qPCR results further confirmed differential expression patterns of the 8 genes between normal and GBM cells, supporting their involvement in GBM pathogenesis. This 8-gene risk model effectively predicts glioma prognosis and supports personalized treatment strategies by highlighting immune microenvironment differences and drug sensitivities between risk groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.